Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Kymab Group Ltd.

Kymab Group Limited ("Kymab") is a leading biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform. Kymouse has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in- class characteristics. The Kymouse naturally matures these molecules to highly potent drugs obviating the need for further time-consuming modifications. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab commenced operations in 2010 and has raised over US$220m of equity financing which includes $100m Series C financing. It has an experienced management team with a successful track record in drug discovery and development and has numerous therapeutic antibody programmes in immuno-oncology, auto-immunity, haematology, infectious disease and other areas. *

 

Period Start 2009-01-01 splitoff
  Group Sanofi (Group) [since May 2011]
  Predecessor Sanger Institute, The Wellcome Trust
Products Industry Kymouse™ technology
  Industry 2 therapeutic antibody
Persons Person Sturge, Simon (Kymab 201905– CEO before Merck (DE) + Boehringer + OctoPlus + Vernalis + Celltech)
  Person 2 Hyland, Anne (Kymab 201503– CFO before BBI Diagnostics + Vectura Group + Celltech + Medeva + KPMG)
     
Region Region Babraham, Cambridgeshire
  Country United Kingdom (GB)
  Street Meditrina /B260)
Babraham Research Campus
  City CB22 3AT Babraham, Cambridgeshire
  Tel +44-1223-833301
    Address record changed: 2020-12-02
     
Basic data Employees B: 11 to 50 (2014-10-31)
     
    * Document for �About Section�: Kymab Group Ltd.. (12/5/16). "Press Release: Antibody Shows Dramatic Post-transplant Benefit".
     
   
Record changed: 2021-04-01

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Sanofi (Group) [since May 2011]


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top